Please use this identifier to cite or link to this item:
|Title:||Therapeutic potential of targeting the renin angiotensin system in portal hypertension.|
|Authors:||Herath, Chandana B;Grace, Josephine A;Angus, Peter W|
|Affiliation:||Chandana B Herath, Josephine A Grace, Department of Medicine, University of Melbourne, Austin Health, Heidelberg, Victoria 3084, Australia.|
|Citation:||World Journal of Gastrointestinal Pathophysiology; 4(1): 1-11|
|Abstract:||Portal hypertension is responsible for the bulk of the morbidity and mortality in patients with cirrhosis. Drug therapy to reduce portal pressure involves targeting two vascular beds. The first approach is to reduce intra hepatic vascular tone induced by the activity of powerful vasocontrictors such as angiotensin II, endothelin-1 and the sympathetic system and mediated via contraction of perisinusoidal myofibroblasts and pervascular smooth muscle cells. The second approach is to reduce mesenteric and portal blood flow. Non-selective β-blockers are widely used and have been shown to prolong patient survival and reduce oesophageal variceal bleeding in advanced cirrhosis. However many patients are unable to tolerate these drugs and they are ineffective in a significant proportion of patients. Unfortunately there are no other drug therapies that have proven efficacy in the treatment of portal hypertension and prevention of variceal bleeding. This review briefly outlines current therapeutic approaches to the management of portal hypertension, and the evidence supporting the role of the renin angiotensin system (RAS) and the use of RAS blockers in this condition. It will also outline recent advances in RAS research that could lead to the development of new treatments focusing in particular on the recently discovered "alternate axis" of the RAS.|
|Internal ID Number:||23596549|
Renin angiotensin system
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.